Filing Analysis
📢 Regulation FD Disclosure
Filed May 12, 2026
⚪ LOW
TherapeuticsMD, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing under Regulation FD.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- Press release issued on May 12, 2026.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Marlan Walker is the current Chief Executive Officer.
📢 Regulation FD Disclosure
Filed Mar 30, 2026
⚪ LOW
TherapeuticsMD, Inc. announced its full-year 2025 financial results on March 30, 2026. The disclosure was made via a press release furnished as Exhibit 99.1 and incorporated by reference into Items 2.02 and 7.01.
📋 Key Facts
- Report date and earliest event date: March 30, 2026.
- Announcement covers the full fiscal year ended December 31, 2025.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- Press release is furnished as Exhibit 99.1.
- Marlan Walker, CEO, signed the report.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.